Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness
Artikel i vetenskaplig tidskrift, 2020

Cancer Medicine published by John Wiley & Sons Ltd. Background: Characterizing breast cancer progression and aggressiveness relies on categorical descriptions of tumor stage and grade. Interpreting these categorical descriptions is challenging because stage convolutes the size and spread of the tumor and no consensus exists to define high/low grade tumors. Methods: We address this challenge of heterogeneity in patient-specific cancer samples by adapting and applying several tools originally created for understanding heterogeneity and phenotype development in single cells (specifically, single-cell topological data analysis and Wanderlust) to create a continuous metric describing breast cancer progression using bulk RNA-seq samples from individual patient tumors. We also created a linear regression-based method to predict tumor aggressiveness in vivo from bulk RNA-seq data. Results: We found that breast cancer proceeds along three convergent phenotype trajectories: luminal, HER2-enriched, and basal-like. Furthermore, 31 296 genes (for luminal cancers), 17 827 genes (for HER2-enriched), and 18 505 genes (for basal-like) are dynamically differentially expressed during breast cancer progression. Across progression trajectories, our results show that expression of genes related to ADP-ribosylation decreased as tumors progressed (while PARP1 and PARP2 increased or remained stable), suggesting the potential for a differential response to PARP inhibitors based on cancer progression. Additionally, we developed a 132-gene expression regression equation to predict mitotic index and a 23-gene expression regression equation to predict growth rate from a single breast cancer biopsy. Conclusion: Our results suggest that breast cancer dynamically changes during disease progression, and growth rate of the cancer cells is associated with distinct transcriptional profiles.

RNA-seq

systems medicine

patient heterogeneity

disease dynamics

Författare

Daniel John Cook

Chalmers, Biologi och bioteknik, Systembiologi

Wallenberg Center for Protein Research (WCPR)

Jonatan Kallus

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Rebecka Jörnsten

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Jens B Nielsen

Novo Nordisk Fonden

Chalmers, Biologi och bioteknik, Systembiologi

Wallenberg Center for Protein Research (WCPR)

BioInnovation Institute

Cancer Medicine

2045-7634 (eISSN)

Vol. 9 10 3551-3562

Ämneskategorier

Medicinsk genetik

Cancer och onkologi

Genetik

DOI

10.1002/cam4.2996

Mer information

Senast uppdaterat

2023-05-26